ATE414541T1 - Vitronectin rezeptor antagonist pharmaka - Google Patents

Vitronectin rezeptor antagonist pharmaka

Info

Publication number
ATE414541T1
ATE414541T1 AT01952180T AT01952180T ATE414541T1 AT E414541 T1 ATE414541 T1 AT E414541T1 AT 01952180 T AT01952180 T AT 01952180T AT 01952180 T AT01952180 T AT 01952180T AT E414541 T1 ATE414541 T1 AT E414541T1
Authority
AT
Austria
Prior art keywords
receptor antagonist
treatment
vitronectin receptor
pharmaceuticals
present
Prior art date
Application number
AT01952180T
Other languages
English (en)
Inventor
Thomas Harris
John Barrett
Alan Carpenter
Milind Rajopadhye
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Application granted granted Critical
Publication of ATE414541T1 publication Critical patent/ATE414541T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AT01952180T 2000-06-21 2001-06-21 Vitronectin rezeptor antagonist pharmaka ATE414541T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21321000P 2000-06-21 2000-06-21

Publications (1)

Publication Number Publication Date
ATE414541T1 true ATE414541T1 (de) 2008-12-15

Family

ID=22794168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952180T ATE414541T1 (de) 2000-06-21 2001-06-21 Vitronectin rezeptor antagonist pharmaka

Country Status (12)

Country Link
EP (1) EP1307226B1 (de)
JP (1) JP2004521066A (de)
CN (1) CN1582166A (de)
AT (1) ATE414541T1 (de)
AU (2) AU2001272965C1 (de)
BR (1) BR0111880A (de)
CA (1) CA2412854C (de)
DE (1) DE60136632D1 (de)
IL (1) IL152941A0 (de)
MX (1) MXPA02012750A (de)
NZ (1) NZ522925A (de)
WO (1) WO2001097848A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2408323C (en) * 2000-05-08 2012-06-12 The University Of British Columbia Drug delivery systems for photodynamic therapy
EP1311292A2 (de) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin rezeptor antagonist pharmaka
CN100356984C (zh) 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
EP1475105A1 (de) * 2003-05-09 2004-11-10 Schering AG Knochengewebegerichtetes Radiopharmaceuticum und Tubulin-interagierende Verbindung kombinatorischer Radiotherapie
WO2004100996A1 (en) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT944619E (pt) * 1996-11-27 2007-01-31 Bristol Myers Squibb Pharma Co Novos antagonistas dos receptores da integrina
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
NZ511677A (en) * 1998-12-18 2003-10-31 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
EP1311292A2 (de) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin rezeptor antagonist pharmaka
EP1296678A2 (de) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Arzneimittel mit vitronektin-rezeptor-antagonistischer wirkung zur anwendung in der kombinationstherapie
WO2001097860A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2002004030A2 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions

Also Published As

Publication number Publication date
CA2412854A1 (en) 2001-12-27
AU2001272965B2 (en) 2005-11-17
DE60136632D1 (de) 2009-01-02
NZ522925A (en) 2006-08-31
JP2004521066A (ja) 2004-07-15
CN1582166A (zh) 2005-02-16
EP1307226B1 (de) 2008-11-19
WO2001097848A3 (en) 2003-03-13
IL152941A0 (en) 2003-06-24
CA2412854C (en) 2010-08-17
AU2001272965C1 (en) 2006-06-29
WO2001097848A2 (en) 2001-12-27
EP1307226A2 (de) 2003-05-07
MXPA02012750A (es) 2004-07-30
AU7296501A (en) 2002-01-02
BR0111880A (pt) 2006-04-25

Similar Documents

Publication Publication Date Title
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A3 (en) Vitronectin receptor antagonist pharmaceuticals
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2000035492A3 (en) Vitronectin receptor antagonist pharmaceuticals
DK1648925T3 (da) Bicyklisk peptid-billeddannende midler
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
CY1110243T1 (el) Ανταγωνιστες npyy5
WO1999058162A3 (en) Pharmaceuticals for the imaging of angiogenic disorders
EP1641423A4 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
BRPI0011856B8 (pt) agonistas de receptor a2a de n-pirazol
DE60136632D1 (de) Vitronectin rezeptor antagonist pharmaka
DE60001983D1 (de) Bicyclische und tricyclische heteroaromatische verbindungen
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
ATE335515T1 (de) Morpholinobildgebung und therapie
NO20031323D0 (no) Peptid-baserte forbindelser
PT1337535E (pt) Derivados de benzodiazepina
ATE332903T1 (de) Kondensierte pyridoindolderivate
DE60001586D1 (de) Diphenyl-piperidin derivate
BR0010802A (pt) Antagonistas de receptor il-8
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
DK1140203T3 (da) Farmaceutiske præparater som vitronectinreceptorantagonist
TR199901761T2 (xx) IL-8 resept�r antagonistleri.
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR200103638T2 (tr) IL-8 Reseptör antagonistleri

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties